{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T13:42:26Z","timestamp":1780407746948,"version":"3.54.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,9,16]],"date-time":"2016-09-16T00:00:00Z","timestamp":1473984000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,9,16]],"date-time":"2016-09-16T00:00:00Z","timestamp":1473984000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA054174"],"award-info":[{"award-number":["CA054174"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s00280-016-3142-3","type":"journal-article","created":{"date-parts":[[2016,9,16]],"date-time":"2016-09-16T08:34:08Z","timestamp":1474014848000},"page":"929-939","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Phase 1 study evaluating the safety and pharmacokinetics of pralatrexate in relapsed\/refractory advanced solid tumors and lymphoma patients with mild, moderate, and severe renal impairment"],"prefix":"10.1007","volume":"78","author":[{"given":"Kevin R.","family":"Kelly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nashat","family":"Gabrail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Weitman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Sarantopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Olszanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Edenfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurgen","family":"Venitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guru","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Hasal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Craig","family":"Lockhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,16]]},"reference":[{"key":"3142_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1146\/annurev-nutr-072610-145133","volume":"31","author":"R Zhao","year":"2011","unstructured":"Zhao R, Diop-Bove N, Visentin M, Goldman ID (2011) Mechanisms of membrane transport of folates into cells and across epithelia. Annu Rev Nutr 31:177\u2013201","journal-title":"Annu Rev Nutr"},{"issue":"9","key":"3142_CR2","first-page":"3493","volume":"6","author":"LM Krug","year":"2000","unstructured":"Krug LM, Ng KK, Kris MG, Miller VA, Tong W, Heelan RT et al (2000) Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate. Clin Cancer Res 6(9):3493\u20133498","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3142_CR3","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s00408-008-9123-5","volume":"187","author":"V Launay-Vacher","year":"2009","unstructured":"Launay-Vacher V, Etessami R, Janus N, Spano JP, Ray-Coquard I, Oudard S et al (2009) Lung cancer and renal insufficiency: prevalence and anticancer drug issues. Lung 187(1):69\u201374","journal-title":"Lung"},{"issue":"5","key":"3142_CR4","first-page":"Cr209","volume":"10","author":"V Launay-Vacher","year":"2004","unstructured":"Launay-Vacher V, Izzedine H, Rey JB, Rixe O, Chapalain S, Nourdine S et al (2004) Incidence of renal insufficiency in cancer patients and evaluation of information available on the use of anticancer drugs in renally impaired patients. Med Sci Monit 10(5):Cr209\u2013Cr212","journal-title":"Med Sci Monit"},{"issue":"8","key":"3142_CR5","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/nrneph.2009.97","volume":"5","author":"V Sahni","year":"2009","unstructured":"Sahni V, Choudhury D, Ahmed Z (2009) Chemotherapy-associated renal dysfunction. Nat Rev Nephrol 5(8):450\u2013462","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"3142_CR6","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1681\/ASN.2004100843","volume":"16","author":"BD Humphreys","year":"2005","unstructured":"Humphreys BD, Soiffer RJ, Magee CC (2005) Renal failure associated with cancer and its treatment: an update. J Am Soc Nephrol 16(1):151\u2013161","journal-title":"J Am Soc Nephrol"},{"key":"3142_CR7","unstructured":"Folotyn [Package Insert] (2011) Allos therapeutics I; Westminster, CO"},{"issue":"1","key":"3142_CR8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/0305-7372(95)90010-1","volume":"21","author":"PE Kintzel","year":"1995","unstructured":"Kintzel PE, Dorr RT (1995) Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev 21(1):33\u201364","journal-title":"Cancer Treat Rev"},{"key":"3142_CR9","unstructured":"Methotrexate [Investigator\u2019s Brochure] (2003) Xanodyne pharmacal; Florence, KY"},{"key":"3142_CR10","unstructured":"Folotyn [Investigator\u2019s Brochure] (2013) Allos therapeutics I; Westminster, CO"},{"issue":"9","key":"3142_CR11","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","volume":"29","author":"OA O\u2019Connor","year":"2011","unstructured":"O\u2019Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B et al (2011) Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 29(9):1182\u20131189","journal-title":"J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-3142-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-016-3142-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-3142-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T11:25:06Z","timestamp":1589628306000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-016-3142-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,16]]},"references-count":11,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["3142"],"URL":"https:\/\/doi.org\/10.1007\/s00280-016-3142-3","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,16]]},"assertion":[{"value":"4 April 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Guru Reddy, Allen Yang, and Steven Hasal are full-time employees of Spectrum Pharmaceuticals Inc. Kevin Kelly has served as a consultant for Spectrum Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}